Brief: Advicenne Expects Marketing Authorisation In U.S On Sibnayal By End-2022

Advicenne SA

15/06/2021 17:03

June 15 (Reuters) - ADVICENNE SA  ADVIC.PA :
    * ADVICENNE 2.0 STRATEGY: PRIORITY IS TO ENTER INTO A
EUROPEAN
COMMERCIAL PARTNERSHIP FOR THE COMMERCIALIZATION OF SIBNAYAL
    * ADVICENNE 2.0 STRATEGY: SECOND PRIORITY IS TO ACCELERATE
THE
CLINICAL DEVELOPMENT OF SIBNAYAL ACROSS THE ATLANTIC IN TWO
INDICATIONS, DRTA AND CYSTINURIA
    * ON SIBNAYAL: EXPECTS TO OBTAIN MARKETING AUTHORISATION IN
UNITED
STATES BY END OF 2022
    * CONTINUES CLINICAL DEVELOPMENT OF SIBNAYAL IN CYSTINURIA
IN
EUROPE AND IN UNITED STATES WITH OBJECTIVE OF A MARKETING
AUTHORISATION RESPECTIVELY IN H1 2023 AND IN H2 2023

Further company coverage:  ADVIC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))